WuXi PharmaTech Set For Sales Synergy with U.S. Subsidiary AppTec
This article was originally published in PharmAsia News
Executive Summary
BEIJING - WuXi PharmaTech, one of China's fastest-growing contract research organizations in the pharmaceutical and medical device sectors, is laying the groundwork to boost earnings through cross-selling synergies with its recently acquired U.S.-based biologics firm AppTec Laboratory Services
You may also be interested in...
WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees
WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees
WuXi PharmaTech Expands J&J Research Deal, Posts Higher Profits
However, firm sees sharper risks sparked by global financial crisis.